Bremelanotide 50mg

✓ A prescription option that works through the brain pathways involved in sexual desire—rather than focusing only on physical arousal.

Bremelanotide, also known as PT-141, is a peptide that activates melanocortin receptors in the central nervous system involved in sexual desire and response.

Unlike treatments focused primarily on genital blood flow, bremelanotide works through signaling in the brain—making it a different approach for women experiencing changes in sexual desire.

When “I Just Don't Feel Interested” Becomes the Problem

Changes in sexual desire are common, and they aren't always the same thing as difficulty becoming physically aroused.

You may still enjoy sex once it begins but notice that you rarely think about it, initiate it or feel the desire you once did.

Bremelanotide has been studied specifically in women experiencing low sexual desire and is designed around that part of the sexual response.

How Bremelanotide Works

Bremelanotide is a peptide and melanocortin receptor agonist.

Rather than acting primarily on blood vessels or reproductive hormones, it activates melanocortin receptors within the central nervous system involved in sexual motivation and response.

Large randomized clinical trials in premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) found statistically significant improvements in sexual desire and reductions in distress associated with low desire compared with placebo.

Desire vs. Physical Arousal

This distinction matters.

Desire is the mental interest or motivation for sexual activity.

Physical arousal involves the body's response—including genital blood flow, sensitivity and lubrication.

Bremelanotide is particularly interesting because its mechanism is centered on brain signaling associated with sexual desire, rather than simply increasing genital blood flow.

For women whose primary concern is physical arousal rather than desire, a different treatment approach may be considered by their provider.

When to Use Bremelanotide

Bremelanotide is generally used as needed before anticipated sexual activity, rather than taken every day.

Your prescribed dose and timing will depend on the specific compounded formulation and instructions provided by your medical provider.

Your Care Journey

• Submit Your Intake – Share your health history, symptoms and treatment goals through our secure online platform.
• Provider Consultation – A licensed provider determines whether bremelanotide is appropriate for you.
• Prescription Approval – If approved, your prescription is coordinated with a licensed compounding pharmacy.
• Treatment Delivered – Medication is shipped directly to your door.
• Continued Care – Providers remain available for questions and follow-up.

Side Effects

Potential side effects of bremelanotide include nausea, flushing, headache, vomiting, injection-site reactions and temporary increases in blood pressure with decreases in heart rate.

Bremelanotide can also cause focal hyperpigmentation, including darkening of areas such as the face, gums and breasts. In some cases, pigmentation may not completely resolve after stopping treatment.

Bremelanotide should not be used in patients with uncontrolled hypertension or known cardiovascular disease.

What We Do / Don’t Do

We Do: Provide telemedicine consultations, connect patients with licensed medical providers, coordinate prescriptions with licensed compounding pharmacies and provide continued treatment support.

We Don’t: Manufacture or dispense medications or guarantee that a prescription will be issued.

Important

The bremelanotide injection offered through Invyncible is a compounded prescription medication. Compounded medications are not FDA-approved or evaluated by FDA for safety, effectiveness or quality before marketing.

FDA-approved bremelanotide (Vyleesi®) is indicated for premenopausal women with acquired, generalized HSDD who meet specific criteria. The compounded bremelanotide offered through Invyncible should not be represented as Vyleesi® or as an FDA-approved generic equivalent.

Individual results may vary.

Invyncible is a telemedicine provider network, not a pharmacy. Prescriptions are filled by licensed pharmacies.

Research & References

Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology. 2019;134(5):899–908.

Clayton AH, et al. Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial. Women's Health. 2016.

Research Context

Research discussed above includes studies of FDA-approved and investigational bremelanotide formulations, doses and methods of administration. It should not be interpreted as clinical evidence that the compounded bremelanotide formulation offered through Invyncible will produce identical outcomes. Individual results may vary.